Mark A. Prygocki Sr. is an Independent Director of the Company. From January 2017 until December 2019, he served as President, Chief Executive Officer and a member of the Board of Directors of Illustris Pharmaceuticals, Inc., a privately held bio-development company. Prior to joining Illustris, Mr. Prygocki worked at Medicis Pharmaceutical Corporation, a biopharmaceutical company, for more than 20 years and served as President from 2010 to 2012. Prior to that, Mr. Prygocki held several senior-level positions at Medicis, including Chief Operating Officer, Executive Vice President, and Chief Financial Officer and Treasurer. Since 2012, Mr. Prygocki has served as a consultant to the pharmaceutical and retail industries through his consulting company. Mr. Prygocki’s previous experience includes work at Citigroup, an investment banking firm, in the regulatory reporting division and several years in the audit department of Ernst & Young, LLP. Mr. Prygocki currently serves on the Board of Directors of Clarus Therapeutics, Inc. and is Chairman of its audit committee. Mr. Prygocki also served on the Board of Directors of Revance Therapeutics, Inc. within the last five years. He is certified by the American Institute of Certified Public Accountants. Mr. Prygocki serves on the board of Whispering Hope Ranch Foundation, a non-profit organization that assists children with special needs. Mr. Prygocki holds a B.S. in accounting from Pace University. Our Board of Directors believes that Mr. Prygocki should serve as a director based upon his operating experience and financial expertise in the biopharmaceutical industry, combined with his prior financial and board positions.
As the Independent Director of Verrica Pharmaceuticals Inc, the total compensation of Mark Prygocki at Verrica Pharmaceuticals Inc is $240,854. There are 5 executives at Verrica Pharmaceuticals Inc getting paid more, with Ted White having the highest compensation of $1,441,190.
Mark Prygocki is 54, he's been the Independent Director of Verrica Pharmaceuticals Inc since 2018. There are 8 older and 6 younger executives at Verrica Pharmaceuticals Inc. The oldest executive at Verrica Pharmaceuticals Inc is Lawrence Eichenfield, 62, who is the Director.
Mark's mailing address filed with the SEC is C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER, PA, 19380.
Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning és John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include: